Top ▲

CYP2C9

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 1326

Nomenclature: CYP2C9

Family: CYP2 family: drug metabolising subset

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 490 10q23.33 CYP2C9 cytochrome P450 family 2 subfamily C member 9
Previous and Unofficial Names Click here for help
(R)-Limonene 6-monooxygenase | (S)-limonene 6-monooxygenase | (S)-limonene 7-monooxygenase | S-mephenytoin 4-hydroxylase | CYP2C10 | cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 9 | cytochrome P450, family 2, subfamily C, polypeptide 9
Database Links Click here for help
Alphafold
BRENDA
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
Pharos
UniProtKB
Wikipedia
Enzyme Reaction Click here for help
EC Number: 1.14.14.51
Description Reaction Reference
(S)-limonene + [reduced NADPH--hemoprotein reductase] + O(2) <=> (-)-trans-carveol + [oxidized NADPH--hemoprotein reductase] + H(2)O
Substrates and Reaction Kinetics Click here for help
Substrate Sp. Property Value Units Standard property Standard value Assay description Assay conditions Comments Reference
sulfaphenazole Hs - -

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 3 [PMID: 18255300] Small molecule or natural product Hs Inhibition 8.4 pKi 5
pKi 8.4 (Ki 4.2x10-9 M) [5]
sulfaphenazole Small molecule or natural product Hs Inhibition 6.5 pKi 1,4
pKi 6.5 (Ki 3x10-7 M) [1,4]
compound 51 [Crosignani et al., 2011] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.7 pIC50 2
pIC50 6.7 (IC50 2x10-7 M) [2]
voxelotor Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 5.1 pIC50 3
pIC50 5.1 (IC50 8.5x10-6 M) [3]
Description: Measuring inhibition of CYP2C9 activity using tolbutamide as substrate.
noscapine Small molecule or natural product Ligand has a PDB structure N/A Inhibition - -
View species-specific inhibitor tables
General Comments
Cytochrome P450 2C9 (CYP2C9) is one of the three major drug metabolizing cytochrome P450 enzymes in human liver.

References

Show »

1. Bourrié M, Meunier V, Berger Y, Fabre G. (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther, 277 (1): 321-32. [PMID:8613937]

2. Crosignani S, Jorand-Lebrun C, Campbell G, Prêtre A, Grippi-Vallotton T, Quattropani A, Bouscary-Desforges G, Bombrun A, Missotten M, Humbert Y et al.. (2011) Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids. ACS Med Chem Lett, 2 (12): 938-42. [PMID:24900284]

3. Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, Lu Q, Partridge JR, Patskovska L, Patskovsky Y et al.. (2017) Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett, 8 (3): 321-326. [PMID:28337324]

4. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. (1988) Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol, 37 (6): 1137-44. [PMID:3355588]

5. Peng CC, Rushmore T, Crouch GJ, Jones JP. (2008) Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9. Bioorg Med Chem, 16 (7): 4064-74. [PMID:18255300]

Contributors

Show »

How to cite this page